VANDAZOLE (metronidazole) by Teva is 12. First approved in 2005.
Drug data last refreshed 36m ago · AI intelligence enriched 3h ago
VANDAZOLE (metronidazole) is a topical nitroimidazole antimicrobial gel approved for vaginal administration. The mechanism of action in treating rosacea remains unknown, though it demonstrates antimicrobial properties at the site of application. Topical metronidazole achieves minimal systemic exposure, with plasma concentrations less than 1% of oral formulations.
Limited commercial opportunity as product approaches loss of exclusivity; support team likely transitioning or consolidating.
12.1 Mechanism of Action The mechanism of action of metronidazole in the treatment of rosacea is unknown. 12.2 Pharmacodynamics The pharmacodynamics of metronidazole in association with the treatment of rosacea are unknown. Cardiac Electrophysiology: The effect of Metronidazole Gel, 1% on the QTc…
Nitroimidazole Antimicrobial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial
A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
Effectivity and Safety of Metronidazole 1% Cream in Rosacea Therapy
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
Worked on VANDAZOLE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moVANDAZOLE offers minimal career advancement potential as a mature, generic-pressured product approaching loss of exclusivity. Career opportunities are primarily in defensive positioning, managed decline, and transition support rather than growth initiatives.